Evolus to Participate in the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Evolus, Inc. (NASDAQ: EOLS), a performance beauty firm, announces participation in the SVB Securities Global Biopharma Conference.

Date: February 14, 2023

Time: 11:20-11:50 am ET

Management will discuss their innovative, customer-centric business model and flagship product, Jeuveau^®, which is the first neurotoxin dedicated to aesthetics. An audio webcast will be available on Evolus' investor relations website, with a replay accessible for 90 days post-event.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the SVB Securities Global Biopharma Conference.

Event:		SVB Securities Global Biopharma Conference.
Date:		Tuesday, February 14, 2023
Time:		11:20-11:50 am ET

An audio webcast of this event will be available on the investor relations section of Evolus’ website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau^® is a registered trademark of Evolus, Inc.
Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005470/en/

Investor/Media Contact:

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

Tel: 949-966-1798

Email: david.erickson@evolus.com

Media Contact:

Email: media@evolus.com

Source: Evolus

FAQ

When is Evolus participating in the SVB Securities Global Biopharma Conference?

Evolus will participate in the SVB Securities Global Biopharma Conference on February 14, 2023.

What time will Evolus' management present at the conference?

Evolus' management will present from 11:20 to 11:50 am ET.

Where can I listen to the Evolus conference presentation?

You can listen to the Evolus conference presentation on their investor relations website at www.evolus.com.

What is the flagship product of Evolus discussed at the conference?

The flagship product of Evolus is Jeuveau^®, which is a neurotoxin dedicated exclusively to aesthetics.

How long will the replay of the Evolus conference presentation be available?

The replay of the Evolus conference presentation will be available for 90 days after the event.